CEO Executive AssistantReal-world evidence has become a strategic imperative in pharmaceutical development and commercialization. Regulatory agencies, payers, and health technology assessment bodies increasingly expect pharmaceutical companies to generate evidence from routine clinical care, electronic health records, claims databases, and disease registries to supplement the randomized controlled trial data that supports approval. FDA’s 21st Century Cures Act framework, EMA’s evolving RWE guidance, and payer demands for real-world effectiveness data have collectively created a new evidence generation obligation that pharmaceutical CEOs must govern with the same rigor as clinical development programs.
Pharma CEO real-world evidence time management is a governance challenge that many pharmaceutical leaders have not yet fully integrated into their strategic planning. RWE programs are not simply observational studies conducted after approval: they require strategic planning that begins at program design, investment in data partnerships and analytics capabilities, and regulatory strategy that anticipates how RWE will be used to support specific labeling and access decisions.
The Strategic Scope of RWE Programs
RWE in pharmaceutical development serves several distinct strategic purposes, and the CEO must ensure the organization’s RWE strategy is explicitly aligned with specific objectives rather than generating data without a defined use case.
Regulatory support. FDA’s RWE framework, established under 21st Century Cures and operationalized through the RWE Program established by FDARA, allows real-world data to support new indications, label modifications, and post-marketing commitments under certain conditions. The CEO must ensure the organization is developing RWE with regulatory-grade rigor where the intended use is regulatory submission, and that FDA’s current thinking on RWE standards for specific use cases is incorporated into study design.
Payer evidence generation. Payers increasingly require demonstration of real-world effectiveness to support formulary positioning, outcomes-based contract design, and prior authorization criteria. RWE that demonstrates superior real-world outcomes compared to alternative therapies, or that identifies the patient subpopulations with the highest treatment response, creates direct commercial value. The CEO must ensure RWE programs for payer purposes are designed with payer evidence standards in mind, not just clinical research standards.
Label expansion. For products with approved indications seeking expansion to additional patient populations, real-world evidence from off-label use in those populations can support a sNDA or sBLA for the expanded indication. The CEO must identify which label expansion opportunities have sufficient real-world evidence potential and ensure that real-world data collection in those populations is established proactively.
Safety pharmacovigilance. Post-marketing safety surveillance increasingly uses real-world data from EHR, claims, and registries to identify safety signals in broader patient populations than clinical trials capture. The CEO’s investment in pharmacovigilance RWE infrastructure serves both safety and regulatory obligations.
Data Partnership Strategy: The CEO’s Investment Decision
RWE generation requires access to real-world data from electronic health records, claims databases, disease registries, or other sources. Securing access to high-quality, fit-for-purpose data is a strategic investment decision that requires CEO involvement.
Key data partnership considerations:
EHR network access. Access to de-identified patient-level EHR data from major health systems requires partnership agreements with data aggregators (companies like Optum, IBM MarketScan, Flatiron Health, or national health data utilities) or direct agreements with health systems. The CEO must ensure the organization has the data access necessary to support its RWE program portfolio, and that data licensing agreements provide the coverage, completeness, and update frequency the RWE programs require.
Disease registry participation and development. Disease registries maintained by academic medical centers, patient advocacy organizations, or specialty societies provide longitudinal patient data in specific disease populations. For pharmaceutical companies with products in rare diseases or specialty therapeutic areas, disease registry access is often the most valuable real-world data source. The CEO’s investment in disease registry development (funding patient registry infrastructure in collaboration with academic or advocacy partners) is both a data strategy and a relationship investment.
Real-world data quality governance. Not all real-world data is suitable for all RWE purposes. Data quality dimensions (completeness, accuracy, consistency, timeliness) vary significantly across data sources, and data that is appropriate for epidemiological characterization may not be appropriate for comparative effectiveness analysis. The CEO must ensure the RWE function has a rigorous data quality evaluation process and that the data sources used for regulatory-grade RWE meet FDA’s current standards for fit-for-purpose data.
The FDA’s Real-World Evidence Program resources provide guidance on FDA’s current expectations for RWE data quality and study design. CEOs should ensure the RWE function is current with FDA’s evolving guidance in this rapidly developing area.
Regulatory RWE Strategy: CEO Engagement Requirements
For RWE intended to support regulatory submissions, the CEO must ensure the organization is engaging FDA proactively to understand the agency’s expectations before investing in large-scale data collection. FDA’s willingness to accept specific types of RWE for specific regulatory purposes varies by indication, data source, and intended use, and the regulatory strategy should be validated through FDA engagement before significant investment is committed.
FDA pre-submission engagement for RWE programs:
Type B meeting requests. For RWE programs intended to support label expansions or post-marketing requirement fulfillment, a Type B meeting request to FDA, describing the proposed RWE study design and data sources, can provide FDA feedback on the study’s acceptability before the study is fully executed. This meeting investment is minor compared to the cost of a fully executed RWE program that FDA ultimately declines to accept.
Master protocol discussions. For companies with multiple RWE programs across different products or indications, a master protocol approach, where common design elements, data sources, and analytical frameworks are shared across programs, can improve regulatory efficiency. FDA has been supportive of master protocol approaches in specific contexts. The CEO should ensure the regulatory strategy explores these efficiencies.
RWE for post-marketing commitments. FDA frequently imposes post-marketing commitments (PMCs) and post-marketing requirements (PMRs) at the time of drug approval. Where RWE approaches are appropriate for fulfilling these commitments, the CEO should ensure the regulatory affairs organization is proposing RWE approaches in PMC negotiations, as they are often more efficient than traditional observational study designs.
For context on how post-approval regulatory commitments integrate into the CEO’s portfolio management, see pharma CEO post-approval commitments.
Analytics Capability: The CEO’s Infrastructure Investment
RWE generation requires advanced analytics capabilities: biostatisticians and epidemiologists who understand observational study design, propensity score methods, causal inference frameworks, and longitudinal data analysis, as well as data engineers who can manage large-scale EHR and claims data processing.
The CEO’s analytics capability investment decisions:
Build versus buy. Most mid-size pharmaceutical companies access RWE analytics capabilities through a combination of internal staff (epidemiologists, outcomes researchers, biostatisticians) and external CRO-type RWE vendors (including IQVIA, ICON, Analysis Group, RTI Health Solutions, and specialty RWE firms). The CEO must ensure the organization has access to the right analytics capabilities for its RWE program portfolio, whether internally or through external partnerships.
Regulatory-grade rigor requirements. RWE analytics for regulatory submissions must meet standards for pre-registration of analysis plans, transparent reporting of analytical decisions, and documentation of data quality assessments. The CEO must ensure the RWE analytics infrastructure is capable of meeting these standards, which are more demanding than typical commercial observational research.
Technology platform investment. RWE analytics increasingly rely on cloud-based data platforms, distributed analytics environments (where analysis is conducted within health system data environments rather than extracting patient data), and federated learning approaches. The CEO must ensure the organization’s technology investment in RWE analytics is keeping pace with methodological and technological advances in the field.
Payer RWE Programs: Commercial Evidence Integration
Payer-facing RWE programs have a different evidence standard than regulatory RWE programs: payers are primarily interested in real-world comparative effectiveness, cost-effectiveness, and total cost of care impacts. The CEO must ensure the payer RWE strategy is co-designed with the market access organization and is aligned with the specific evidence gaps that payers have identified as barriers to favorable formulary positioning or outcomes-based contracting.
Effective payer RWE programs:
Comparative effectiveness studies. Studies comparing the real-world effectiveness of the company’s product against the treatment alternatives that payers are currently covering provide the head-to-head evidence that formulary committees find most relevant. Study design must control for confounding through appropriate methods (propensity score matching, regression adjustment, instrumental variables) to generate credible comparative effectiveness estimates.
Total cost of care analyses. Payers respond to evidence that the company’s product reduces total healthcare costs (hospitalizations, emergency department visits, downstream complications) even if the drug cost is higher than alternatives. Total cost of care analyses using claims data are among the most persuasive RWE designs for payer audiences.
Patient subgroup analyses. Real-world data can identify patient subpopulations with particularly strong treatment response, which can inform prior authorization criteria that concentrate drug use in patients most likely to benefit. These analyses serve both the payer’s interest in cost-effective drug use and the company’s interest in ensuring its product is used in appropriate patients.
Time Architecture for RWE Program Governance
A practical time architecture for pharma CEO real-world evidence time management:
Strategic RWE portfolio review. Annual review of the RWE program portfolio, covering: what RWE programs are active, what specific regulatory, payer, or label expansion objectives each program serves, what data sources are being used, and what timeline and budget is required. This is a strategic governance review, not an operational status meeting.
Regulatory RWE strategy reviews. For any RWE program intended for regulatory submission, CEO review at the program design stage (to confirm alignment with FDA engagement and regulatory strategy) and at the reporting stage (to review the data package before regulatory submission).
Payer evidence committee participation. The CEO should participate in at least an annual payer evidence strategy review, ensuring the RWE program portfolio is aligned with the commercial access objectives for the most strategically important products.
Data partnership governance. Annual review of data partnership agreements, data source quality assessments, and any data access issues that could affect program delivery. Significant new data partnership decisions should involve CEO review of the strategic and financial terms.
Conclusion
Pharma CEO real-world evidence time management reflects a fundamental shift in the pharmaceutical evidence landscape. The randomized controlled trial remains the evidentiary gold standard for efficacy and safety in regulatory submissions, but it is no longer sufficient by itself for regulatory success in all settings, for payer coverage decisions, or for sustained post-approval market access. CEOs who govern RWE strategy with the rigor it requires, who invest in data partnerships and analytics capabilities that enable credible RWE generation, and who engage FDA proactively on regulatory RWE strategy create pharmaceutical programs that are positioned for success in an evidence environment that will only become more demanding over time.
Related Reading
For further context, explore How Pharma CEOs Balance Regulatory Affairs and Commercial Time and How Pharma CEOs Manage Time During Major Conference Season.